Supply Chain Resiliency KPIs Every C‑Suite Should Track and How to Get the Data

How product-centric metrics and verified data turn boardroom risk conversations into action

Supply chain resiliency has moved from the warehouse to the boardroom. For health systems, disruption is no longer a hypothetical risk. It is a scheduled certainty. Hospitals face an average of 50 drug shortages at any given time, and device backorders have become a near-permanent feature of post-pandemic procurement. Yet many organizations are still stuck in reactive mode, leaning on surface-level metrics like backorder counts and supplier scorecards to gauge how prepared they really are.

The problem with those metrics is that they only tell you what has already gone wrong. They do not tell you what is about to. Health system executives need a sharper approach: a focused set of product-centric KPIs built on accurate, current, and fully enriched data. Real resiliency cannot be measured through transactional logs alone. It depends on the quality of the product intelligence underneath them.

Key Finding: According to the FDA, drug shortages cost U.S. hospitals an estimated $359 million annually in labor costs alone, plus another $200 million to source and validate alternative products. That is over half a billion dollars a year spent reacting to problems that better data could help prevent.

Why Leadership Needs Product-Centric Metrics

Most supply chain dashboards are built around what already happened. They show last quarter's backorders, last month's spend, last week's supplier performance. That backward-looking view is useful for reporting, but it does almost nothing to prepare a health system for what is coming next.

Product-level KPIs flip that script. They surface risk before it disrupts operations or erodes margin. They give leadership a clear view of where concentration is building, how ready the organization is to substitute critical products, and whether the underlying data is strong enough to support business continuity decisions when it matters most.

The AHRMM Cost, Quality, and Outcomes (CQO) Movement has been making this case for years, identifying data quality and clinical integration as the foundation of supply chain performance. When hospitals tie operational KPIs to verified product data, they stop chasing fires and start getting ahead of them.

The Core Resiliency KPIs That Matter

Most health systems can start with three core metrics. Together they give a clear picture of supply stability and organizational readiness. Each one depends on granular, validated data from the item master, not rolled-up summaries from supplier portals or ERP reports.

1. Percentage of High-Risk Items with Validated Substitutes

If you could only track one resiliency metric, this would be it. It measures how ready the organization is to keep care moving when a key product goes on backorder, gets recalled, or simply disappears from the market.

High-risk typically means clinically critical, single-source, manufactured in a single geography, or subject to regulatory sensitivity. A joint survey by the AHA, FAH, and ASHP found that more than 90% of hospitals had to identify alternative therapies to manage drug shortages, and nearly 80% said the process was extremely challenging. That same difficulty plays out across devices and supplies every time a disruption hits.

What this KPI is really measuring is preparation. Have clinically acceptable alternatives been identified, reviewed, and loaded into purchasing systems before the next shortage? Hospitals that do this work in advance stop scrambling when a product goes down. They pull up a vetted list and move on.

Target State: Every clinically critical, single-source item has at least one validated substitute mapped and pre-approved in the ERP before the next backorder event.

2. Spend Exposure by Country of Origin or Tariff Region

Trade risk has become a real operational concern for health systems, not just a macroeconomic headline. The tariff changes that took effect in 2025 produced reported cost increases of 16% to 25% on products sourced from major trade partners, and most hospitals had no clear picture of how much of their spend was in the crosshairs.

The underlying exposure is significant. Roughly 62% of medical devices used in the U.S. are imported, with close to 70% of certain device categories made exclusively overseas. More than 90% of generic sterile injectable drugs rely on active pharmaceutical ingredients from India or China. Without item-level origin data, health systems cannot see what portion of their spend is vulnerable, let alone do anything about it before costs shift.

This KPI tracks the percentage of total spend tied to specific regions or carrying exposure to active or potential tariffs. With that view in hand, leadership can balance sourcing portfolios, anticipate cost volatility, and model the financial impact of trade policy changes before they show up as budget surprises.

Getting the data right here requires country-of-origin information that is verified at the item level, through FDA manufacturer registrations and supplier label images, rather than self-reported fields in the item master that may not have been touched in years.

Executive Question: If tariffs on medical products from one major trade partner jumped 25% tomorrow, how much of your annual spend would be affected? Do you know which categories carry the most exposure?

3. Share of the Item Master That Is Fully Enriched and Maintained

The first two KPIs only work if the data behind them is solid. This third metric is about data quality itself: what percentage of items in the item master carry validated attributes, including manufacturer identifiers, GTIN, classification codes, packaging levels, country of origin, and regulatory information.

In practice, most item masters have significant gaps. Manufacturer information is inconsistent, catalog numbers are unverified, and country of origin is either missing or out of date. Those gaps compound over time as new products are added, products are recalled, and regulatory classifications change.

A high enrichment score means the organization has the foundation it needs to make resiliency metrics trustworthy across procurement, logistics, and clinical systems. It also reflects a governance commitment. Data quality is not a project with an end date. It is an ongoing discipline that requires clear ownership and regular upkeep.

How to Capture and Maintain the Right Data

Tracking these KPIs requires data that is complete, consistent, and kept current. The starting point is unifying item master records across ERP, clinical, and vendor systems so every product has a verified identity that can be enriched and monitored over time.

From there, enrichment fills in the missing layers: country of origin, tariff classification, substitute mapping, clinical and operational attributes, and regulatory data. That process is what turns a static item file into a genuine product intelligence layer, one that supports daily operations and long-term resiliency planning at the same time.

Keeping that data current is just as important as building it. The Healthcare Industry Resilience Collaborative (HIRC), a network of more than 1,200 hospitals, has built its work around exactly this challenge. By establishing shared standards for item normalization, validated substitutes, and resiliency indicators, HIRC helps risk signals improve across the whole industry rather than requiring each health system to solve the problem in isolation.

Governance ties it all together. When there is clear accountability for ongoing data maintenance, quality stays high as market conditions shift. When resiliency metrics are integrated into financial and operational dashboards, leadership sees them in real time instead of discovering problems months after they have already affected operations.

From KPIs to Strategic Conversations

The real payoff of product-centric resiliency metrics is a change in the conversation at the leadership level. Supply chain stops being a topic that surfaces when something breaks and becomes a discipline that gets managed proactively, the same way finance and clinical quality are managed.

With the right KPIs in place, leadership sees the concentration of single-source, single-geography critical items before the next shortage hits. Finance models tariff exposure across the full spend portfolio before trade policy shifts. And instead of treating data quality as a known problem that never gets fixed, the organization has a metric for it, a target, and someone accountable for hitting it.

The AHRMM CQO framework describes this shift as moving supply chain from reactive cost management to proactive clinical and operational alignment, where sourcing decisions reflect full awareness of both clinical requirements and supply risk. Product-centric KPIs are what make that kind of alignment measurable and sustainable.

Bottom Line: Resiliency is not a feeling or a general sense that things are under control. It is a set of metrics grounded in verified product data, and like any other operational capability, it can be measured, tracked, and improved.

The Role of Symmetric Health Solutions

Symmetric Health Solutions gives hospitals the data foundation they need to calculate, monitor, and act on meaningful resiliency KPIs. The platform enriches item masters with verified manufacturer, origin, and clinical attributes, maps clinically comparable substitutes across categories and manufacturers, and confirms country of origin through FDA registrations and manufacturer label images.

A resiliency control tower pulls together product, contract, spend, and risk signals so supply chain and finance teams can see clinical and supply implications side by side. Health systems have used it to model potential tariff impacts across tens of millions of dollars in spend and to identify substitute options for critical items well before the next shortage event. Helping shift the industry as a whole from reactive firefighting toward preparedness that is grounded in trusted, shared data.